Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

被引：0

作者：

Ariens, Lieneke F. M. ^{[1
]}

Bakker, Daphne S. ^{[1
]}

Spekhorst, Lotte S. ^{[1
]}

Van der Schaft, Jorien ^{[1
]}

Thijs, Judith L. ^{[1
]}

Haeck, Inge ^{[2
]}

Flinterman, Annebeth E. ^{[3
]}

Kamsteeg, Marijke ^{[4
]}

Schuttelaar, Marie L. A. ^{[5
]}

De Bruin-Weller, Marjolein S. ^{[1
]}

机构：

[1] Univ Med Ctr Utrecht, Natl Expertise Ctr Atop Dermatitis, Dept Dermatol & Allergol, NL-3584 CX Utrecht, Netherlands

[2] Reinier Graaf Gasthuis, Dept Dermatol, Delft, Netherlands

[3] Diakonessen Hosp, Utrecht, Netherlands

[4] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands

[5] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands

来源：

ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷

关键词：

atopic dermatitis; dupilumab; health-economics; absenteeism; presenteeism;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included. Absenteeism, presenteeism, and related costs at baseline and during follow-up were calculated using the Work Productivity and Activity Impairment questionnaire. A total of 218 adult patients with moderate-to-severe atopic dermatitis were included. Total work impairment reduced significantly from baseline (35.5%) to week 52 (11.5%), p < 0.001. Median weekly productivity losses reduced significantly from baseline ((sic)379.8 (140.7-780.8)) to week 52 ((sic)0.0 (0.0-211.0), p < 0.001). In this study, dupilumab treatment demonstrated a significant improvement in work productivity and reduction in associated costs in a large cohort of patients with difficult-to-treat atopic dermatitis in daily practice.

引用

页数：5

共 50 条

[1] Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
Ariens, Lieneke F. M.
Bakker, Daphne S.
Spekhorst, Lotte S.
Van der Schaft, Jorien
Thijs, Judith L.
Haeck, Inge
Flinterman, Annebeth E.
Kamsteeg, Marijke
Schuttelaar, Marie L. A.
De Bruin-Weller, Marjolein S.
[J]. ACTA DERMATO-VENEREOLOGICA, 2021, 101
[2] Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the Bioday registry
Ariens, L. F.
Van der Schaft, J.
Bakker, D. S.
Balak, D.
Romeijn, M.
Kouwenhoven, T.
Kamsteeg, M.
Giovannone, B.
Knol, E. F.
Drylewicz, J.
Van Wijk, F.
Nierkens, S.
Thijs, J. L.
Schuttelaar, M.
De Bruin-Weller, M. S.
[J]. ALLERGY, 2019, 74 : 581 - 582
[3] Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
Ariens, Lieneke F. M.
van der Schaft, Jorien
Bakker, Daphne S.
Balak, Deepak
Romeijn, Margreet L. E.
Kouwenhoven, Tessa
Kamsteeg, Marijke
Giovannone, Barbara
Drylewicz, Julia
van Amerongen, Cynthia Catalina Aurora
Delemarre, Evelien M.
Knol, Edward F.
van Wijk, Femke
Nierkens, Stefan
Thijs, Judith L.
Schuttelaar, Marie L. A.
de Bruin-Weller, Marjolein S.
[J]. ALLERGY, 2020, 75 (01) : 116 - 126
[4] FIRST REAL-WORLD EVIDENCE OF UPADACITINIB TREATMENT IN PATIENTS WITH DIFFICULT-TO-TREAT ATOPIC DERMATITIS: RESULTS FROM THE BIODAY REGISTRY
Boesjes, Celeste M.
van der Gang, Lian F.
Zuithoff, Nicolaas P. A.
Bakker, Daphne S.
Spekhorst, Lotte S.
de Graaf, Marlies
de Bruin-Weller, Marjolein S.
[J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 38 - 38
[5] Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry
Spekhorst, Lotte S.
Ariens, Lieneke F. M.
van Der Schaft, Jorien
Bakker, Daphne S.
Kamsteeg, Marijke
Oosting, Albert J.
De Ridder, Ilona
Sloeserwij, Annemiek
Romeijn, Geertruida L. E.
De Graaf, Marlies
Haeck, Inge
Thijs, Judith L.
Schuttelaar, Marie L. A.
de Bruin-Weller, Marjolein S.
[J]. ALLERGY, 2020, 75 (09) : 2376 - 2379
[6] Risk factors for conjunctivitis in atopic dermatitis patients treated with dupilumab: results from the bioday registry
Achten, R.
Van der Rijst, L.
Bakker, D.
Spekhorst, L.
Boesjes, C.
Zuithoff, N.
Knol, E.
Van Luijk, C.
De Boer, J.
Thijs, J.
De Graaf, M.
De Bruin-Weller, M.
[J]. ALLERGY, 2021, 76 : 11 - 11
[7] Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry
van der Rijst, Lisa P.
Groot, Karin M. de Winter-de
Zuithoff, Nicolaas P. A.
de Bruin-Weller, Marjolein S.
de Graaf, Marlies
[J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2024, 35 (06)
[8] The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry
Voorberg, Angelique N.
Romeijn, Geertruida L. E.
de Bruin-Weller, Marjolein S.
Schuttelaar, Marie L. A.
[J]. CONTACT DERMATITIS, 2022, 87 (02) : 185 - 191
[9] Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
Boesjes, Celeste M.
van der Gang, Liana F.
Zuithoff, Nicolaas P. A.
Bakker, Daphne S.
Spekhorst, Lotte S.
Haeck, Inge
Kamsteeg, Marijke
de Graaf, Marlies
de Bruin-Weller, Marjolein S.
[J]. ACTA DERMATO-VENEREOLOGICA, 2023, 103
[10] Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry
Kamphuis, Esme
Boesjes, Celeste M.
Loman, Laura
Bakker, Daphne S.
Poelhekken, Mila
Zuithoff, Nicolaas P. A.
Kamsteeg, Marijke
Romeijn, Geertruida L. E.
van Wijk, Femke
de Bruin-Weller, Marjolein S.
de Graaf, Marlies
Schuttelaar, Marie L. A.
[J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2022, 33 (12)

← 1 2 3 4 5 →